Guilian Xu

Guilian Xu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MTMing Tang
Ming Tang
XCXu Cao
Xu Cao
KZKun Zhang
Kun Zhang
YLYou Li
You Li
QZQuan-You Zheng
Quan-You Zheng
KZKe-Qin Zhang
Ke-Qin Zhang
Renal fibrosis is the final manifestation of various chronic kidney diseases, and no effective therapy is available to prevent or reverse it. Celastrol, a triterpene that derived from traditional Chinese medicine, is a known potent anti-fibrotic agent. However, the underlying mechanisms of action of celastrol on renal fibrosis remain unknown. In this study, we found that celastrol treatment remarkably attenuated unilateral ureteral obstruction (UUO)-induced mouse renal fibrosis. This was evidenced by the significant reduction in tubular injury; collagen deposition; accumulation of fibronectin, collagen I, and α-smooth muscle actin; and the expression levels of pro-fibrotic factors Vim, Cola1, and TGF-β1 mRNA, as well as inflammatory responses. Celastrol showed similar effects in a folic acid-induced mouse renal fibrosis model. Furthermore, celastrol potentiated the expression of the anti-fibrotic factor cannabinoid receptor 2 (CB2R) in established mouse fibrotic kidney tissues and transforming growth factor β1 (TGF-β1)-stimulated human kidney 2 (HK-2) cells. In addition, the CB2R antagonist (SR144528) abolished celastrol-mediated beneficial effects on renal fibrosis. Moreover, UUO- or TGF-β1-induced activation of the pro-fibrotic factor SMAD family member 3 (Smad3) was markedly inhibited by celastrol. Inhibition of Smad3 activation by an inhibitor (SIS3) markedly reduced TGF-β1-induced downregulation of CB2R expression. In conclusion, our study provides the first direct evidence that celastrol significantly alleviated renal fibrosis, by contributing to the upregulation of CB2R expression through inhibiting Smad3 signaling pathway activation. Therefore, celastrol could be a potential drug for treating patients with renal fibrosis.

1 January 2018 in Cancer Letters
Verified
Journal Article
Closed access
JCJian Chen
Jian Chen
GLGui-Qing Li
Gui-Qing Li
LZLi Zhang
Li Zhang
MTMing Tang
Ming Tang
XCXu Cao
Xu Cao
YWYuzhang Wu
Yuzhang Wu

18 June 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
QZQuan‐You Zheng
Quan‐You Zheng
FXFeng Xu
Feng Xu
YYYi Yang
Yi Yang
DSDao‐Dong Sun
Dao‐Dong Sun
YZYu Zhong
Yu Zhong
SLShen‐Ju Liang
Shen‐Ju Liang
Psoriasis is a chronic relapsing inflammatory skin disease, affecting up to 3% of the global population. Accumulating evidence suggests that the complement system is involved in its pathogenesis. Our previous study revealed that the C5a/C5aR1 pathway is crucial for disease development. However, the underlying mechanisms remain largely unknown. To explore potential mechanisms, psoriatic skin lesions and histological changes were assessed following imiquimod (IMQ) cream treatment. Inflammatory cytokine expression was tested by real‐time RT‐PCR. Immunohistochemistry and flow cytometry were used to identify inflammatory cell infiltration and interleukin (IL‐17A) IL‐17A expression. A C5aR1 antagonist (C5aR1a) and PI3K inhibitor (wortmannin) were used for blocking experiments (both in vivo and in vitro) to explore the mechanism. C5a/C5aR1‐pathway inhibition significantly attenuated psoriasis‐like skin lesions with decreased epidermal hyperplasia, downregulated type 17‐related inflammatory gene expression, and reduced IL‐17A‐producing γδ‐T cell responses. Mechanistically, C5a/C5aR1 promoted the latter phenotype via PI3K‐Akt signaling. Consistently, C5aR1 deficiency clearly ameliorated IMQ‐induced chronic psoriasiform dermatitis, with a significant decrease in IL‐17A expression. Finally, blocking C5aR1 signaling further decreased psoriasiform skin inflammation in IL‐17‐deficient mice. Results suggest that C5a/C5aR1 mediates experimental psoriasis and skin inflammation by upregulating IL‐17A expression from γδ‐T cells. Blocking C5a/C5aR1/IL‐17A axis is expected to be a promising strategy for psoriasis treatment.

1 October 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SWShun Wu
Shun Wu
MLMeng Li
Meng Li
FXFeng Xu
Feng Xu
GLGui-Qing Li
Gui-Qing Li
BHBo Han
Bo Han
GXGuilian Xu
Guilian Xu
Renal fibrosis has no effective target for its prevention or reversal. Fibinogen-like protein 2 (Fgl2) is a novel prothrombinase exhibiting coagulation activity and immunomodulatory effects. Although Fgl2 is known to play a vital role in the development of liver and interstitial fibrosis, its function in renal fibrosis remains unclear. In this study, Fgl2 expression was found to be markedly increased in kidney tissues from mice with unilateral ureteral obstruction (UUO)-induced renal fibrosis and patients with chronic kidney disease. However, Fgl2 deficiency aggravated UUO-induced renal fibrosis, as evidenced by the significantly increasing collagen I, fibronectin, and α-SMA expression, extracellular matrix deposition, and profibrotic factor (TGF-β1) secretion. Administration of rmFgl2 (recombinant mouse Fgl2) significantly alleviated UUO-induced renal fibrosis in mice, suggesting that the increased fibrosis can be reversed by supplementing rmFgl2. Although there was no difference in the percentages of total macrophages between Fgl2+/+ and Fgl2-/- mice, Fgl2 deficiency remarkably facilitated M2 macrophage polarization and accelerated M1 macrophage polarization to a low degree, during UUO-induced renal fibrosis development in mice. Similar results were observed when Fgl2+/+ and Fgl2-/- mice bone marrow-derived macrophages were treated for M1 or M2 polarization. Moreover, Fgl2 deficiency significantly increased the phosphorylation of STAT6, a critical mediator of M2 polarization, in both UUO-induced fibrotic kidney tissues and bone marrow-derived M2 macrophages. In conclusion, the aggravation of renal fibrosis by Fgl2 deficiency is facilitated by the p-STAT6-dependent upregulation of macrophage polarization, especially of M2.

1 August 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
QZQuan-You Zheng
Quan-You Zheng
SLShen-Ju Liang
Shen-Ju Liang
FXFeng Xu
Feng Xu
YYYi Yang
Yi Yang
JFJian-Li Feng
Jian-Li Feng
GXGuilian Xu
Guilian Xu

1 December 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
YYYan Yang
Yan Yang
LMLi Meng
Li Meng
SWShun Wu
Shun Wu
YLYou Li
You Li
YZYu Zhong
Yu Zhong
KPKan-Fu Peng
Kan-Fu Peng